- Home
- DALN vs VRCA Comparison
DALN vs VRCA Comparison
Compare DALN & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DALN
- VRCA
- Stock Information
- Founded
- DALN 1954
- VRCA 2013
- Country
- DALN United States
- VRCA United States
- Employees
- DALN N/A
- VRCA N/A
- Industry
- DALN Newspapers/Magazines
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- DALN Consumer Discretionary
- VRCA Health Care
- Exchange
- DALN Nasdaq
- VRCA Nasdaq
- Market Cap
- DALN 38.1M
- VRCA 43.0M
- IPO Year
- DALN 2008
- VRCA 2018
- Fundamental
- Price
- DALN $4.36
- VRCA $0.44
- Analyst Decision
- DALN
- VRCA Hold
- Analyst Count
- DALN 0
- VRCA 5
- Target Price
- DALN N/A
- VRCA $6.00
- AVG Volume (30 Days)
- DALN 24.5K
- VRCA 242.5K
- Earning Date
- DALN 04-30-2025
- VRCA 05-13-2025
- Dividend Yield
- DALN N/A
- VRCA N/A
- EPS Growth
- DALN N/A
- VRCA N/A
- EPS
- DALN 5.56
- VRCA N/A
- Revenue
- DALN $123,414,000.00
- VRCA $7,566,000.00
- Revenue This Year
- DALN N/A
- VRCA $127.58
- Revenue Next Year
- DALN N/A
- VRCA $88.06
- P/E Ratio
- DALN $0.78
- VRCA N/A
- Revenue Growth
- DALN N/A
- VRCA 47.66
- 52 Week Low
- DALN $2.98
- VRCA $0.38
- 52 Week High
- DALN $7.86
- VRCA $11.41
- Technical
- Relative Strength Index (RSI)
- DALN 42.22
- VRCA 44.12
- Support Level
- DALN $4.25
- VRCA $0.39
- Resistance Level
- DALN $4.62
- VRCA $0.48
- Average True Range (ATR)
- DALN 0.32
- VRCA 0.05
- MACD
- DALN 0.00
- VRCA -0.00
- Stochastic Oscillator
- DALN 7.46
- VRCA 44.95
About DALN DallasNews Corporation Series A
DallasNews Corp is a local news and information publishing company in Texas with commercial printing, distribution, and direct mail capabilities, as well as a presence in emerging media and digital marketing.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.